Der hier verfügbare Newsfeed wird von unserem Content-Partner Business Wire bereitgestellt. Es handelt sich dabei um einen der bedeutendsten und reichweitenstärksten Pressedienste, die Nachrichten, Pressemitteilungen und Multimedia-Inhalte an Medien, Journalisten und der Öffentlichkeit zur Verfügung stellen. Business Wire ist ein Tochterunternehmen des Warren-Buffett-Konzerns Berkshire Hathaway.
Der NewsWire-Hub ("X-Billboard") umfasst derzeit vfünf der wichtigsten internationalen Nachrichtenquellen und wird durch einen Börseninformationsservice ergänzt. Die einzelnen Newswire-Services ergänzen sich und bilden ein komplementäres Informationsangebot, mehr als drei Viertel der offiziellen Nachrichtenquellen ab, auf die sich Redaktionen weltweit bei ihrer Börsenberichterstattung stützen. Ihr Vorteil: Sie finden hier alles in einer Übersicht. Über die Steuerelemente können Sie zu den einzelnen Bereichen navigieren. Im Terminalview können Sie gezielt auf Unternehmensebene individuelle Recherchen durchführen.
Systemstatus: 20.839 Nachrichten wurden bislang erfolgreich verarbeitet
Business Wire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
US14843C1053
Letzte Aktualisierung: 22.12.2024 | 6AM
Kennen Sie bereits den neuen Terminal-View? Folgen Sie bei Interesse dem folgenden Link.
FIGI: BBG006YWVSR3
CSTL

Castle Biosciences, Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Diagnostics & Research
NAME
Castle Biosciences, Inc.
ISIN
US14843C1053
TICKER
CSTL
MIC
XNAS
REUTERS
CSTL.OQ
BLOOMBERG
CSTL US
Do., 19.12.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 13, 2024, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 135 employees covering an aggregate of 173,542 shares of common stock as an inducement material to...
Do., 12.12.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new independent meta-analysis in Cancers assessing the efficacy of its DecisionDx-Melanoma test in predicting melanoma patient outcomes. The article, titled “The Prognostic Value of the 31-Gene ...
Mi., 20.11.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024, at 10:50 a.m. Eastern time. A live audio webcast of the C...
Di., 19.11.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been named a Houston Top Workplace for 2024 by the Houston Chronicle. This is the fourth consecutive year the Company has been ranked among the Houston metro area’s top workplaces. Castle also earned thr...
Fr., 08.11.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data highlighting the clinical performance of its DecisionDx-Melanoma and MyPath Melanoma tests at the American Society of Dermatopathology (ASDP) 61st Annual Meeting, being held Nov. 7-10, in Chicago. “At Castle, w...
Do., 07.11.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone for the Company’s TissueCypher Barrett’s Esophagus test, which surpassed 25,000 test reports delivered since the Company acquired the test at the end of 2021. “At Castle, improving patient c...
Mi., 06.11.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the latest data from its prospective, multicenter DECIDE study exploring the impact of integrating DecisionDx-Melanoma test results into SLNB decision-making for patients recently diagnosed with melanoma. The update...
Mo., 04.11.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2024. “We are thrilled with our third quarter performance, which reflects the continued success of our growth initiatives and the dedi...
Di., 29.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating a significant reduction in healthcare management costs and an improvement in the quality of life for patients with Barrett’s esophagus (BE) whose management is guided by its TissueCypher test....
Mo., 28.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the following investor conferences next month: Guggenheim Securities Healthcare Innovation Conference on Nov. 11, 2024, at 2:30 p.m. East...
So., 20.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data supporting the clinical utility of its DecisionDx-Melanoma and DecisionDx-SCC tests in guiding risk-aligned treatment decisions, including SLNB for patients with melanoma and surveillance imaging for those ...
Mi., 16.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of two recent studies that provide further support for the clinical need of its MyPath® Melanoma gene expression profile (GEP) test, designed to aid in providing an accurate diagnosis for ambiguous m...
Mo., 14.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2024, after the close of market on Monday, Nov. 4, 2024. Company management will host a conference call and webcast t...
Fr., 11.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will sponsor the 71st Annual Montagna Symposium on the Biology of the Skin, hosted by the Oregon Health & Science University (OHSU) Department of Dermatology and being held Oct. 17-21, 2024, in Stevenson...
Mi., 09.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will present new data related to its DecisionDx-Melanoma and DecisionDx®-UM tests for patients with cutaneous melanoma (CM) and uveal melanoma (UM), respectively, at the 21st International Congress of the So...
Mi., 02.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will hold a groundbreaking ceremony to celebrate the recent construction start of its new corporate campus and office building. The ceremony will take place on Oct. 22, 2024, at 10:00 a.m. Central time at th...
Fr., 27.09.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the ability of its DecisionDx-SCC test to provide clinically impactful risk stratification in high-risk SCC patient sub-populations (i.e., patients with suppressed immune systems in this study...
Mo., 23.09.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data supporting the ability of its TissueCypher Barrett’s Esophagus test (TSP-9) to independently predict risk of progression to esophageal cancer in patients with Barrett’s esophagus (BE) at the American Foregut S...
Mo., 16.09.2024       Castle Biosciences

The Arizona Bioindustry Association, Inc. (AZBio) and Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Kristen Oelschlager, R.N., Castle’s chief operating officer, has been named the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year. The award, prese...
Mi., 11.09.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study further demonstrating that DecisionDx-Melanoma can precisely predict sentinel lymph node (SLN) positivity risk to help guide risk-aligned SLNB decisions, potentially reducing the numbe...

Die hier zur Verfügung gestellten Informationen unterliegen keiner redaktionellen Bearbeitung. Die Aufbereitung erfolgt vollautomatisch und wird durch Zusatzinformationen und weiterführende Recherchemöglichkeiten angereichert. Ziel der Inhalte ist die schnelle und unkomplizierte Versorgung der Informationssuchenden mit den für sie relevanten Informationen. Durch eine Rückverlinkung auf den Informationsanbieter und -eigentümer ist sichergestellt, dass die hier aufbereiteten Daten bei Bedarf mit den Quellinformationen abgeglichen werden können. Das Newsboard zeigt keine Informationen in Echtzeit. Diese bitten wir bei Bedarf beim Börsenbetreiber abzurufen. Es besteht kein Anspruch auf Vollständigkeit. Hochverfügbarkeit kann nicht gewährleistet werden. Sollten Sie Fehler in der Funktionsweise bemerken, teilen Sie uns diese über das weiter unten befindliche Formular "Report a Bug" mit.

RAW DATA PROCESSING bedeutet, dass Rohdaten verarbeitet werden, ohne den Inhalt zu verändern. Um die Interpretation der Information im Sinne der Nutzbarkeit zu verbessern, werden die Daten ergänzt. 

Hinweis: Über das Newswire-Crosslink-Panel im oberen Bereich gelangen Sie schnell und bequem zu weiteren Informationsquellen. Im Terminalview sind die Nachrichten auf Unternehmensebene gefiltert und ermöglich darüber gezielte Recherchen.


Wir bedanken uns im Namen der Investoren-Community bei BusinessWire für die Bereitstellung der News- und Datenfeeds